Physician profile
Brian E Ohara
NPI 1568459113
$1,138.88
in general payments reported to CMS, 2019-2025
19 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $206 · 2021: $15.30 · 2022: $11.71 · 2023: $51.32 · 2024: $195 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $205.15 | 2019-2025 | Farxiga |
| Astellas Pharma US INC | $167.33 | 2019-2020 | |
| Amgen INC. | $117.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.10 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $88.45 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $85.55 | 2019-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $51.01 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $39.13 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.35 | 2019 | |
| Neurocrine Biosciences, INC. | $37.06 | 2024-2025 | Ingrezza |
| Exact Sciences Corporation | $33.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $29.34 | 2025 | General - Pain Management |
| Janssen Pharmaceuticals, INC | $26.24 | 2019-2020 | |
| Pfizer INC. | $25.11 | 2019-2025 | |
| Abbvie INC. | $22.50 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.58 | 2024 | Rexulti |
| Dexcom, INC. | $18.62 | 2023 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $15.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ohara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.